Research programme: nuclear importation inhibitors - Presidio Pharmaceuticals
Alternative Names: CNI-H0294; H0294; ITI-001; PPI-367Latest Information Update: 01 Jun 2010
At a glance
- Originator Cytokine PharmaSciences; Presidio Pharmaceuticals
- Class Pyrimidines; Small molecules
- Mechanism of Action Nuclear importation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections; HIV-1 infections
Most Recent Events
- 12 Jan 2007 Preclinical compounds and NEXT™ technology licensed to Presidio Pharmaceuticals worldwide
- 29 Sep 2006 This programme is still in active development
- 12 Aug 2002 Preclinical trials in HIV infections in USA (unspecified route)